Chongqing Huabang Shengkai Pharmaceutical

Chongqing Huabang Shengkai Pharmaceutical is a leading Chinese pharmaceutical enterprise and a core subsidiary of the publicly traded Huabang Health. The company is a dominant player in the domestic dermatology market, specializing in the research, development, and large-scale manufacturing of treatments for acne, psoriasis, and various forms of dermatitis. Its product portfolio includes well-known brands of isotretinoin, tretinoin, and halometasone, alongside a significant presence in the anti-tuberculosis and oncology therapeutic areas. Operating from advanced GMP-certified facilities in Chongqing, the company integrates R&D with high-capacity production to serve both Chinese and international markets. Huabang Shengkai is recognized as a High-Tech Enterprise in China, consistently investing in generic drug consistency evaluations and the development of new formulations.